ArticleCurrent topics in behavioral neurosciences2022
Disease Modification in Epilepsy: Behavioural Accompaniments.
Article in Current topics in behavioral neurosciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 2 citations in OpenAlex.
- Evaluation of metformin for epilepsy prevention or seizure control in people without evidence of diabetes: retrospective cohort study.Journal of neurology, neurosurgery, and psychiatry · 2026Article
- Tactile stimulation of young WAG/Rij rats prevents development of depression but not absence epilepsy.Frontiers in behavioral neuroscience · 2024Article
- Disease modification in inflammatory skin disorders: opportunities and challenges.Nature reviews. Drug discovery · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
According to the definition of epileptogenesis, "disease modification" refers to every clinically relevant therapeutic outcome which does not necessarily prevent epilepsy onset but significantly improves the disease course by reducing seizure burden and/or decreases concomitant comorbidities. In this light, understanding comorbidities development, their characteristics, and the neurobiological causes represents a major issue both in clinical and preclinical research. This chapter is summarizing and critically evaluating the preclinical improvements over time in the study of epilepsy comorbidities reconsidering some of them according to the newer results. Furthermore, we highlight limitations and possibilities both in the methods used and in the mechanisms considered. The latter have been analysed also as potential therapeutic targets for therapy development. Finally, differences and similarities between induced epilepsy models and genetic models have been underlined in the chapter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.